Damora Therapeutics, Inc.
NASDAQDamora Therapeutics walks into its May 14 earnings release with short sellers having nearly doubled their positions in six weeks — a striking build in a small-cap biotech that has already shed 11% over the past month. Short interest has climbed from roughly 1.2% of the free float in late March to close to 3% now, a gain of more than 128% in a month. The borrow market reflects that…
Snapshot as of 22 Jun 2026
Damora Therapeutics walks into its May 14 earnings release with short sellers having nearly doubled their positions in six weeks — a striking build in a small-cap biotech that has already shed 11% over the past…
Damora Therapeutics walks into its May 7 earnings report carrying two distinctly uncomfortable facts: a CFO who just stepped down and a short interest that has tripled in six weeks. The headline from Monday — CFO Lori…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DMRA — free to start on ORTEX.
Sign up for free →Open DMRA on ORTEX